|
|
|
14.01.26 - 06:12
|
Ascentage: Partnership With Takeda Going Well (Bloomberg)
|
|
|
Dajun Yang, Co-founder, Chairman and CEO at Ascentage Pharma, says he hopes the company's partnership with Takeda on a blood cancer therapy could be ready for commercialization in two years. He speaks on "Bloomberg: The China Show" ahead of his presentation at the JPMorgan Healthcare Conference in San Francisco. (Source: Bloomberg)...
|
|
|
09.01.26 - 12:48
|
Takeda and Halozyme sign global agreement for Enhanze technology (PBR)
|
|
|
Through this partnership, Takeda aims to enhance patient care while exploring new opportunities for vedolizumab. Marketed as Entyvio, vedolizumab is approved for adults with moderately to severely active
The post Takeda and Halozyme sign global agreement for Enhanze technology appeared first on Pharmaceutical Business review....
|
|
|
|
|
|
|
06.01.26 - 12:24
|
Takeda and Protagonist seek FDA approval for rusfertide to treat PV (PBR)
|
|
|
The first-in-class, subcutaneously administered hepcidin mimetic peptide, rusfertide is intended to regulate iron homeostasis and red blood cell production to help manage haematocrit levels in PV patients. The
The post Takeda and Protagonist seek FDA approval for rusfertide to treat PV appeared first on Pharmaceutical Business review....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
05.12.25 - 11:12
|
Takeda and Innovent fulfil close conditions for ADC and IO therapies (PBR)
|
|
|
In October 2025, the two companies signed the deal as part of their focus on bispecifics and ADCs. The agreement aims to expedite the worldwide development and commercialisation
The post Takeda and Innovent fulfil close conditions for ADC and IO therapies appeared first on Pharmaceutical Business review....
|
|
|
05.12.25 - 03:15
|
INNOVENT BIO Completes Introduction of Takeda, Raising ~HKD780M Net (AAStocks)
|
|
|
In October 2025, INNOVENT BIO (01801.HK) announced a global strategic partnership with Takeda Pharmaceutical (4502.JP). This partnership involves a licensing agreement valued at USD11.4 billion and a USD100 million strategic equity investment from Takeda.INNOVENT BIO announced that all conditions precedent to each of the license......
|
|
|
|
|
|
|
03.12.25 - 16:36
|
insitro Appoints R&D Veteran Stephen Hitchcock and AI Visionary Vijay Pande as Scientific Advisors (Business Wire)
|
|
|
Former Takeda CSO and a16z Bio + Health Founder to Guide Clinical Translation and Scaling of insitro's ChemML™ Platform
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--insitro, the AI therapeutics company built on causal biology, today announced the appointment of two scientific advisors: Stephen Hitchcock, Ph.D., a preeminent drug development leader and former Chief Scientific Officer of Takeda, and Vijay Pande, Ph.D., co-founder of VZVC and, previously, founder and General Partner of Andreessen Horowitz's Bio + Health fund.
Hitchcock and Pande will advise on the continued development and scaling of insitro's AI-driven ChemML™ platform as it is deployed across insitro's pipeline and partner programs. Their guidance will focus on translating compelling targets into the medicinal chemistry and preclinical development strategies required to advance therapeutics into clinical trials – connecting computational prediction with the realities of drug development at scale.
“Drug discovery often falters ...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
